Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 531 of 6351
-
Stem cell showdown: donor or self? new trial aims to improve lymphoma outcomes
Disease control Recruiting nowThis study is a multicenter, two-arm, prospective clinical trial, comprising two groups: the allogeneic hematopoietic stem cell transplantation group (Allo-HSCT) and the autologous hematopoietic stem cell transplantation group (Auto-HSCT). It aims to evaluate the efficacy and saf…
Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New hope for advanced bowel cancer: experimental drug combo enters major trial
Disease control Recruiting nowThe purpose of this study is to evaluate the safety and efficacy of pumitamig in combination with chemotherapy versus bevacizumab in combination with chemotherapy in participants with previously untreated, unresectable, or metastatic colorectal cancer
Phase 2/3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New combo therapy targets liver tumors from eye cancer
Disease control Recruiting nowThis Phase 2 study evaluates the efficacy and safety of sequential treatment with percutaneous hepatic perfusion (PHP) using melphalan/HDS followed by tebentafusp in patients with metastatic uveal melanoma (mUM) with isolated liver metastases. The rationale is that PHP enhances a…
Phase 2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New cocktail targets Stomach-Lining pancreatic cancer
Disease control Recruiting nowThis goal of this clinical trial is to learn whether the drug combination of intraperitoneal paclitaxel (chemotherapy given directly into the abdominal cavity) and intravenous NALIRIFOX (chemotherapy given into a vein, including fluorouracil, leucovorin, oxaliplatin, and liposoma…
Phase 1 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New mpox vaccine trial launches in DRC: could it be a game changer?
Vaccine Not yet recruitingTo evaluate the safety and immunogenicity of the MVA-SIBP vaccine using a double-blind, randomized, controlled, age de-escalation design conducted in Kinshasa, Democratic Republic of the Congo (DRC).
Phase 2 • Sponsor: Shanghai Institute Of Biological Products • Aim: Vaccine
Last updated Jun 27, 2026 08:00 UTC
-
New cell therapy offers hope for Hard-to-Treat lymphoma patients
Disease control Not yet recruitingEvaluate the safety and tolerability of AcNK-Sup003 cell injection in subjects with relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). To preliminarily determine the Maximum Tolerated Dose (MTD) or recommended clinical dose of AcNK-Sup003 cell injection.
Sponsor: Donghua Zhang • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Blood test may predict liver cancer comeback and immunotherapy success
Knowledge-focused Not yet recruitingHepatocellular carcinoma (HCC) is a leading global cause of cancer-related mortality. While curative resection is pivotal, high postoperative recurrence rates remain a major challenge. Adjuvant immune checkpoint inhibitors (ICIs) show promise in improving outcomes, but biomarkers…
Sponsor: Tongji Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
New four-drug cocktail targets tough liver cancers with promising early trial
Disease control Not yet recruitingIn China, the majority of hepatocellular carcinoma (HCC) cases stem from chronic hepatitis B virus (HBV) infection and subsequent cirrhosis, with patients often presenting at the decompensated stage complicated by clinically significant portal hypertension (CSPH). CSPH not only l…
Phase 2 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
One-Shot gene therapy could free PKU patients from strict diet
Disease control Not yet recruitingThis study is a single-arm, open-label, dose-escalation, exploratory study to evaluate the safety, tolerability, and efficacy of a single administration of GS1168 Injection in Chinese adult phenylketonuria (PKU) with PAH mutation.
Early phase 1 • Sponsor: Gritgen Therapeutics Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New breast cancer cocktail aims to ditch chemo before surgery
Disease control Not yet recruitingTo further enhance treatment efficacy, minimize reliance on chemotherapy, and identify the optimal neoadjuvant approach for ER-positive and HER2-positive population, we have designed a single-arm, phase II clinical trial. This study aims to evaluate the efficacy and safety of a n…
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Can a smart platform ease the toll of childhood cancer on families?
Symptom relief Recruiting nowThis multicenter randomized controlled trial aims to develop and evaluate two Smart Holistic Health Care Platforms (SHHCPs) for families of children with cancer in Taiwan: the Parent Smart Holistic Health Care Platform (P-SHHCP) for parents and the Child Smart Holistic Health Car…
Sponsor: National Defense Medical University, Taiwan • Aim: Symptom relief
Last updated Sep 06, 2026 00:00 UTC
-
New combo aims to shrink liver tumors before surgery
Disease control Recruiting nowThis study is a prospective, single-arm, phase Ⅱtrial. The subjects are patients resectable centrally-located hepatocellular carcinoma in BCLC stage B who are admitted to the Hepatobiliary Surgery Department of Tongji Hospital , Tongji Medical College, Huazhong University of Scie…
Phase 2 • Sponsor: Wei Zhang • Aim: Disease control
Last updated Jun 26, 2026 14:09 UTC
-
New hope for esophageal cancer: triple therapy enters major trial
Disease control Not yet recruitingThis is a multicenter phase 2/3 clinical study to evaluate the efficacy and safety of SYS6010 plus SG001±5-FU/Capecitabine as first-line treatment, in patients with advanced/metastatic esophageal squamous cell carcinoma.
Phase 2/3 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New dissolving heart plug could stop strokes without lifelong drugs
Disease control Not yet recruitingTo evaluate the Safety and Efficacy of a Novel Biodegradable Occluder for Percutaneous Closure of Patent Foramen Ovale (PFO)
Sponsor: Shanghai Lingsi Medical Technology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New hope for rare genetic disorder: tailored chemo before stem cell transplant
Disease control Not yet recruitingNijmegen breakage syndrome is one of the DNA repair defect disorders. A characteristic feature of these syndromes is a predisposition to the development of malignant neoplasms. The only curative option for the combined immunodeficiency in Nijmegen breakage syndrome is allogeneic …
Phase 2 • Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Glowing probe could help surgeons spot stomach cancer edges
Diagnosis Not yet recruitingRadical surgery remains the primary treatment for gastric cancer, but intraoperative tumor margin assessment relies on surgeons' visual inspection, limiting accuracy. There is thus an urgent clinical need for real-time visualisation of tumour margins. In recent years, near-infra…
Sponsor: Nanfang Hospital, Southern Medical University • Aim: Diagnosis
Last updated Jun 27, 2026 08:03 UTC
-
New hope for hard-to-treat ovarian cancer: drug duo shows promise in early trial
Disease control Not yet recruitingAs one of the gynecological malignancies with the highest incidence and mortality rates worldwide, ovarian cancer treatment faces the significant challenge of platinum-resistant recurrence. Patients with platinum-resistant recurrent ovarian cancer (PROC) have an extremely poor pr…
Phase 2 • Sponsor: The First Affiliated Hospital of Zhengzhou University • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New Dual-Action therapy targets Hard-to-Treat prostate cancer
Disease control Not yet recruitingThis is a single-arm, open-label, Phase I/II clinical study designed to evaluate the safety, tolerability, pharmacokinetics, dosimetry, pharmacodynamics, and preliminary efficacy of Gallium \[68Ga\] PSMA-0057 Injection and Lutetium \[177Lu\] PSMA-0057 Injection as an integrated t…
Phase 1/2 • Sponsor: Chengdu StarRay Therapeutics Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Gene therapy injection aims to halt vision loss in AMD patients
Disease control Recruiting nowThis is a clinical study to evaluate the safety, tolerability and efficacy of CTx001, administered via a single subretinal injection, for GA (secondary to AMD). Safety and efficacy will be measured at regular intervals for 2 years after which long-term safety will be assessed an…
Phase 1/2 • Sponsor: Complement Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New heart valve device offers hope for patients too sick for surgery
Disease control Not yet recruitingThe purpose of the study is to evaluate the safety and effectiveness of the HighLife transcatheter trans-septal mitral valve replacement (TSMVR) system in NYHA Class ≥ II-IV patients with moderate-to-severe or severe mitral regurgitation (MR) who, by assessment of the local Heart…
Sponsor: HighLife SAS • Aim: Disease control
Last updated Jun 26, 2026 17:26 UTC